Inactivated rabies vaccines: Standardization of an in vitro assay for residual viable virus detection

Abstract

Human rabies, a neglected viral zoonosis, is preventable through domestic animals vaccination and post-exposure prophylaxis using inactivated rabies vaccines. During vaccine production, several mandatory in vivo quality control trials, such as potency, live virus, and safety, are responsible for the use of large numbers of laboratory animals. Over the years, global organizations encouraged the development of alternative methods to reduce, replace and refine the use of animals in the pharmaceutical industry. In this study we standardized an in vitro assay for determination of residual live virus combining viral isolation techniques with direct immunofluorescence detection and viral quantification by a molecular method. Standardization of viral recovery steps and quantification by RT-qPCR were performed and the combined method was shown to be 3 fold more sensitive than the in vivo assay. It was possible to identify viral suspensions cultures, which still had residual viable rabies virus particles, evidencing the importance to implement this method in quality control schemes of rabies vaccine production. In addition, this developed assay is more practical, inexpensive and less time consuming, producing results in just 4 days, which may allow greater agility in the internal quality control of the vaccine. The in vitro method may reduce 2/3 rd of laboratory animals numbers used for this purpose, since it can be applied in the intermediate quality control of inactivated rabies vaccine production.

Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness

“…Despite that, this technology remains the primary choice for managing many pathogens, including Influenza, SARS, MERS, etc., since other technologies, such as recombinant polypeptides, have not been able to successfully imitate the pathogen's epitope configuration. Thus, this classic strategy is efficiently used to produce vaccines for hepatitis A [83], flu viruses [84], and rabies [85]. Now, the same strategy is used to develop a vaccine for COVID-19.…”

<i>In vitro</i> methods for rabies virus detection, and evaluation of their use in the production of rabies immunoglobulin

“…Указанные особенности явились основанием для применения ОТ-ПЦР-РВ в производстве антирабических препаратов, в частности, для количественной оценки содержания антигена в материале для иммунизации продуцентов антирабической сыворотки 15 . Неоднократно отмечено использование ОТ-ПЦР-РВ в комплексе с методами иммунофлуоресценции для оценки полноты инактивации вируса при изготовлении вакцин [57][58][59].…”

Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine

“…Classical inactivated whole virus particle vaccines (WPVs) have been used for preventing seasonal influenza 21 and other infectious diseases [22][23][24][25] . In the production of inactivated vaccines, inactivation is a crucial step to ensure the vaccine is safe for use.…”